Rituximab plus CHOP (R-CHOP) has been proven to increase overall survival in aggressive bcl-2-positive lymphoma patients. Using competing risk analysis, we studied the long-term impact of this treatment in patients from a GELA trial: R-CHOP prevented from progression or relapse in both bcl-2-positive and bcl-2-negative patients without increasing the risk of death in complete remission.
Figures & Tables
Vol. 91 No. 5 (2006): May, 2006 : Letters to the Editor
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com
How to Cite
N Mounier, J Briere, C Gisselbrecht, F Reyes, P Gaulard, B Coiffier, Groupe d’Etude des Lymphomes de l’Adulte. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 2006;91(5):715-716; https://doi.org/10.3324/%x.